Investigating the role of angiogenesis in systemic lupus erythematosus
- 30 October 2014
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 24 (6), 621-627
- https://doi.org/10.1177/0961203314556293
Abstract
We aimed to elucidate the roles of six pro-angiogenic factors, namely, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), in the pathogenesis of systemic lupus erythematosus (SLE). A group of 75 patients with SLE and a control group of 40 healthy volunteers were recruited. Angiogenic factors were tested through enzyme-linked immunosorbent assay (ELISA) measurement. The angiogenic activities of the patients with SLE and the healthy controls were assessed and a correlation analysis of these angiogenic factors was conducted. A much higher level of angiogenic activity was shown in the serum of patients with SLE than that of the healthy controls, yet no statistically significant difference was found in the angiogenic activities of active SLE and inactive SLE. Serum VEGF level in the active SLE group was significantly higher than that in the control group and the inactive SLE group, and serum HGF level was strongly positively correlated with VEGF in all SLE groups; meanwhile, there was also a statistically significant positive correlation between TNF-alpha and VEGF in all SLE groups. There was a statistically significant positive correlation between serum VEGF level and bFGF level in the active SLE group. There was a slightly negative correlation between serum HGF level and TGF-beta level in the SLE group, but this negativity did not reach the significance level. Likewise, positive correlation was also shown in the serum VEGF level and PlGF level, yet not in bFGF with PlGF. Circulating serum angiogenic cytokines may be disease markers of SLE activity. Anti-angiogenic agents such as thalidomide and endogenous angiogenesis inhibitors such as endostatin are potentially effective and promising therapies in the treatment of SLE.This publication has 37 references indexed in Scilit:
- The association of single nucleotide polymorphism within vascular endothelial growth factor gene with systemic lupus erythematosus and lupus nephritisInternational Journal of Immunogenetics, 2011
- Angiogenic activity in sera of patients with systemic lupus erythematosusLupus, 2009
- TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult MicrovasculaturePLOS ONE, 2009
- Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosusLupus, 2009
- Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosusPediatric Allergy and Immunology, 2007
- Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolideAutoimmunity, 2007
- Vascular Endothelial Growth Factor and AngiogenesisPharmacological Reviews, 2004
- Serum concentrations of basic fibroblast growth factor in collagen diseasesJournal of the American Academy of Dermatology, 1996
- The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities: IMPLICATIONS FOR A FUNCTIONAL ROLE OF PLACENTA GROWTH FACTOR IN MONOCYTE ACTIVATION AND CHEMOTAXISOnline Journal of Public Health Informatics, 1996
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences of the United States of America, 1993